State Street
FULC icon

State Street’s Fulcrum Therapeutics FULC Stock Holding History

State Street’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.46M Buy
2,037,025
+487,174
+31% +$2.96M ﹤0.01% 2833
2026
Q1 		$11.9M Buy
1,549,851
+544,506
+54% +$5.05M ﹤0.01% 2523
2025
Q4 		$11.4M Sell
1,005,345
-57,862
-5% -$589K ﹤0.01% 2580
2025
Q3 		$9.78M Sell
1,063,207
-155,159
-13% -$1.12M ﹤0.01% 2652
2025
Q2 		$8.38M Sell
1,218,366
-34,074
-3% -$182K ﹤0.01% 2687
2025
Q1 		$3.61M Buy
1,252,440
+7,121
+0.6% +$26.2K ﹤0.01% 3013
2024
Q4 		$5.85M Sell
1,245,319
-434,910
-26% -$1.6M ﹤0.01% 2891
2024
Q3 		$6M Buy
1,680,229
+638,955
+61% +$4.74M ﹤0.01% 2875
2024
Q2 		$6.46M Buy
1,041,274
+784,413
+305% +$5.94M ﹤0.01% 2808
2024
Q1 		$2.42M Buy
256,861
+73,714
+40% +$658K ﹤0.01% 3219
2023
Q4 		$1.24M Hold
183,147
– – ﹤0.01% 3437
2023
Q3 		$813K Sell
183,147
-22,800
-11% -$99.7K ﹤0.01% 3574
2023
Q2 		$680K Sell
205,947
-759,641
-79% -$2.23M ﹤0.01% 3631
2023
Q1 		$2.75M Buy
965,588
+185,174
+24% +$1.66M ﹤0.01% 3220
2022
Q4 		$5.68M Buy
780,414
+54,897
+8% +$358K ﹤0.01% 2989
2022
Q3 		$5.87M Buy
725,517
+76,851
+12% +$550K ﹤0.01% 2985
2022
Q2 		$3.18M Sell
648,666
-27,288
-4% -$267K ﹤0.01% 3319
2022
Q1 		$16M Sell
675,954
-21,957
-3% -$311K ﹤0.01% 2556
2021
Q4 		$12.3M Buy
697,911
+245,599
+54% +$4.87M ﹤0.01% 2790
2021
Q3 		$12.8M Buy
452,312
+140,087
+45% +$2.65M ﹤0.01% 2741
2021
Q2 		$3.27M Buy
312,225
+57,728
+23% +$584K ﹤0.01% 3428
2021
Q1 		$3M Buy
254,497
+15,048
+6% +$186K ﹤0.01% 3268
2020
Q4 		$2.8M Buy
239,449
+27,394
+13% +$310K ﹤0.01% 3230
2020
Q3 		$1.68M Buy
212,055
+4,957
+2% +$59.7K ﹤0.01% 3272
2020
Q2 		$3.79M Buy
207,098
+12,836
+7% +$202K ﹤0.01% 2903
2020
Q1 		$2.32M Buy
194,262
+155,213
+397% +$2.48M ﹤0.01% 2994
2019
Q4 		$650K Buy
+39,049
New +$373K ﹤0.01% 3483

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street's FULC Position: Q2 2026 in Review

State Street increased its Fulcrum Therapeutics (FULC) stake by 31% in Q2 2026, buying an estimated $2.96M and bringing the position to 2,037,025 shares worth $7.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2833.

State Street first reported a position in FULC in Q4 2019 and has held it in 27 quarters since. The position peaked at $16M in Q1 2022. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • State Street held 2,037,025 shares of Fulcrum Therapeutics worth $7.46M as of Q2 2026.
  • State Street bought 487,174 Fulcrum Therapeutics shares in Q2 2026, an estimated $2.96M.
  • Fulcrum Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2833 holding.
  • State Street first reported a position in Fulcrum Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • State Street's Fulcrum Therapeutics position peaked at $16M in Q1 2022.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.